17.0571 USD
-0.06 (-0.37%)
PHAR gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. While PHAR has a great health rating, its profitability is only average at the moment. PHAR has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
In the past year PHAR has reported negative net income.
PHAR had a positive operating cash flow in the past year.
In multiple years PHAR reported negative net income over the last 5 years.
In multiple years PHAR reported negative operating cash flow during the last 5 years.
1.2 Ratios
With an excellent Return On Assets value of 0.02%, PHAR belongs to the best of the industry, outperforming 89.31% of the companies in the same industry.
With an excellent Return On Equity value of 0.04%, PHAR belongs to the best of the industry, outperforming 90.81% of the companies in the same industry.
With an excellent Return On Invested Capital value of 7.52%, PHAR belongs to the best of the industry, outperforming 93.43% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.02% | ||
| ROE | 0.04% | ||
| ROIC | 7.52% |
ROA(3y)-0.72%
ROA(5y)2.18%
ROE(3y)-1.26%
ROE(5y)5.02%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHAR has a Profit Margin of 0.03%. This is amongst the best in the industry. PHAR outperforms 89.68% of its industry peers.
The Operating Margin of PHAR (10.15%) is better than 92.12% of its industry peers.
PHAR has a better Gross Margin (89.90%) than 91.56% of its industry peers.
PHAR's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.15% | ||
| PM (TTM) | 0.03% | ||
| GM | 89.9% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), PHAR is creating some value.
PHAR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PHAR has more shares outstanding
The debt/assets ratio for PHAR has been reduced compared to a year ago.
2.2 Solvency
PHAR has an Altman-Z score of 4.13. This indicates that PHAR is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of PHAR (4.13) is better than 73.36% of its industry peers.
The Debt to FCF ratio of PHAR is 2.49, which is a good value as it means it would take PHAR, 2.49 years of fcf income to pay off all of its debts.
PHAR has a better Debt to FCF ratio (2.49) than 93.25% of its industry peers.
A Debt/Equity ratio of 0.46 indicates that PHAR is not too dependend on debt financing.
The Debt to Equity ratio of PHAR (0.46) is worse than 70.92% of its industry peers.
Even though the debt/equity ratio score it not favorable for PHAR, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 2.49 | ||
| Altman-Z | 4.13 |
ROIC/WACC1.08
WACC6.97%
2.3 Liquidity
PHAR has a Current Ratio of 3.16. This indicates that PHAR is financially healthy and has no problem in meeting its short term obligations.
PHAR has a worse Current ratio (3.16) than 61.91% of its industry peers.
A Quick Ratio of 2.40 indicates that PHAR has no problem at all paying its short term obligations.
With a Quick ratio value of 2.40, PHAR is not doing good in the industry: 68.48% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.16 | ||
| Quick Ratio | 2.4 |
3. Growth
3.1 Past
PHAR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 96.30%, which is quite impressive.
Looking at the last year, PHAR shows a very strong growth in Revenue. The Revenue has grown by 26.78%.
Measured over the past years, PHAR shows a quite strong growth in Revenue. The Revenue has been growing by 10.64% on average per year.
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%
3.2 Future
Based on estimates for the next years, PHAR will show a very strong growth in Earnings Per Share. The EPS will grow by 61.94% on average per year.
Based on estimates for the next years, PHAR will show a quite strong growth in Revenue. The Revenue will grow by 9.43% on average per year.
EPS Next Y227.95%
EPS Next 2Y134.62%
EPS Next 3Y79.43%
EPS Next 5Y61.94%
Revenue Next Year18.75%
Revenue Next 2Y15.45%
Revenue Next 3Y15.46%
Revenue Next 5Y9.43%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
PHAR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 36.90, PHAR can be considered very expensive at the moment.
Based on the Price/Forward Earnings ratio, PHAR is valued cheaper than 90.62% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 35.79. PHAR is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 36.9 |
4.2 Price Multiples
PHAR's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. PHAR is cheaper than 93.81% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, PHAR is valued cheaply inside the industry as 94.18% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 22.23 | ||
| EV/EBITDA | 21.06 |
4.3 Compensation for Growth
PHAR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of PHAR may justify a higher PE ratio.
PHAR's earnings are expected to grow with 79.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y134.62%
EPS Next 3Y79.43%
5. Dividend
5.1 Amount
PHAR does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:PHAR (11/25/2025, 4:30:00 PM)
17.0571
-0.06 (-0.37%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners14.71%
Inst Owner Change0.22%
Ins Owners1.38%
Ins Owner ChangeN/A
Market Cap1.17B
Revenue(TTM)362.27M
Net Income(TTM)100.00K
Analysts88.57
Price Target17.76 (4.12%)
Short Float %0.01%
Short Ratio0.42
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)597.09%
Min EPS beat(2)123.3%
Max EPS beat(2)1070.87%
EPS beat(4)2
Avg EPS beat(4)281.14%
Min EPS beat(4)-42.39%
Max EPS beat(4)1070.87%
EPS beat(8)3
Avg EPS beat(8)65.03%
EPS beat(12)5
Avg EPS beat(12)12.9%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)4.89%
Min Revenue beat(2)1.11%
Max Revenue beat(2)8.68%
Revenue beat(4)4
Avg Revenue beat(4)8.65%
Min Revenue beat(4)1.11%
Max Revenue beat(4)13.37%
Revenue beat(8)5
Avg Revenue beat(8)1.62%
Revenue beat(12)7
Avg Revenue beat(12)-0.52%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-16.6%
PT rev (3m)-4.49%
EPS NQ rev (1m)63.43%
EPS NQ rev (3m)93.14%
EPS NY rev (1m)-55.18%
EPS NY rev (3m)2580.67%
Revenue NQ rev (1m)7.7%
Revenue NQ rev (3m)16.56%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 36.9 | ||
| P/S | 3.23 | ||
| P/FCF | 22.23 | ||
| P/OCF | 21.97 | ||
| P/B | 4.41 | ||
| P/tB | 8.99 | ||
| EV/EBITDA | 21.06 |
EPS(TTM)-0.01
EYN/A
EPS(NY)0.46
Fwd EY2.71%
FCF(TTM)0.77
FCFY4.5%
OCF(TTM)0.78
OCFY4.55%
SpS5.29
BVpS3.87
TBVpS1.9
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.02% | ||
| ROE | 0.04% | ||
| ROCE | 9.52% | ||
| ROIC | 7.52% | ||
| ROICexc | 13.21% | ||
| ROICexgc | 34.23% | ||
| OM | 10.15% | ||
| PM (TTM) | 0.03% | ||
| GM | 89.9% | ||
| FCFM | 14.51% |
ROA(3y)-0.72%
ROA(5y)2.18%
ROE(3y)-1.26%
ROE(5y)5.02%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.48%
GM growth 5Y0.17%
F-Score7
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.46 | ||
| Debt/FCF | 2.49 | ||
| Debt/EBITDA | 2.31 | ||
| Cap/Depr | 4.03% | ||
| Cap/Sales | 0.17% | ||
| Interest Coverage | 6 | ||
| Cash Conversion | 101.53% | ||
| Profit Quality | 52570% | ||
| Current Ratio | 3.16 | ||
| Quick Ratio | 2.4 | ||
| Altman-Z | 4.13 |
F-Score7
WACC6.97%
ROIC/WACC1.08
Cap/Depr(3y)9.71%
Cap/Depr(5y)59.68%
Cap/Sales(3y)0.61%
Cap/Sales(5y)3.49%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)96.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%600%
EPS Next Y227.95%
EPS Next 2Y134.62%
EPS Next 3Y79.43%
EPS Next 5Y61.94%
Revenue 1Y (TTM)26.78%
Revenue growth 3Y14.33%
Revenue growth 5Y10.64%
Sales Q2Q%30%
Revenue Next Year18.75%
Revenue Next 2Y15.45%
Revenue Next 3Y15.46%
Revenue Next 5Y9.43%
EBIT growth 1Y357.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year279.47%
EBIT Next 3Y79.88%
EBIT Next 5Y88.46%
FCF growth 1Y309.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y325%
OCF growth 3YN/A
OCF growth 5YN/A
PHARMING GROUP NV - ADR / PHAR FAQ
Can you provide the ChartMill fundamental rating for PHARMING GROUP NV - ADR?
ChartMill assigns a fundamental rating of 6 / 10 to PHAR.
What is the valuation status of PHARMING GROUP NV - ADR (PHAR) stock?
ChartMill assigns a valuation rating of 6 / 10 to PHARMING GROUP NV - ADR (PHAR). This can be considered as Fairly Valued.
Can you provide the profitability details for PHARMING GROUP NV - ADR?
PHARMING GROUP NV - ADR (PHAR) has a profitability rating of 6 / 10.
What is the earnings growth outlook for PHARMING GROUP NV - ADR?
The Earnings per Share (EPS) of PHARMING GROUP NV - ADR (PHAR) is expected to grow by 227.95% in the next year.